Dimitroulakos Lab

Jim Dimitroulakos profile picture

Contact Information

Jim Dimitroulakos, PhD
613 737-7700 x70335

Ottawa Hospital Research Institute
Cancer Centre Building
501 Smyth Road
Box 926
Ottawa, ON
K1H 8L6

What We Do

My laboratory has two main research themes revolving around the identification of novel therapeutic approaches in the treatment of epithelial cancers including lung, head and neck and prostate carcinomas.

Selected Publications

Mevalonate Pathway
1. A Phase I Study of the Combination of High-Dose Rosuvastatin with Erlotinib in Patients with Advanced Solid Malignancies. Glenwood D. Goss, Derek J. Jonkers, Scott A. Laurie, Amit M.Oza, Michael M. Vickers, Charles la Porte and Jim Dimitroulakos. (Under Review, J Transl Med)  
2. Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS, Weberpals JI, Dimitroulakos J. Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors. Mol Cancer Ther, 13(11):2559-71, 2015.  
3. Zhao TT, LeFrancois BG, Goss G, Ding K, Bradbury PA, Dimitroulakos J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation through targeting rho proteins. Oncogene. 29(33):4682-92, 2010.

ATF3 as a Regulator of Platin-Induced Cytotoxicity
1. Induction of Activating Transcription Factor 3 is associated with cisplatin responsiveness in NSCLC: A potential predictive biomarker of response. Jair Bar, Ivan Gorn-Hondermann, Mohammed S. Hasim, Theodore Perkins, Michael Rudnicki, David Stewart, Glenwood D. Goss, Harmon Sekhon, James Villeneuve  and Jim Dimitroulakos. (Under Review, Cancer Research)
2. O’Brien A, Barber JEL, Reid S, Niknejad N, Dimitroulakos J. Enhancement of cisplatin cytotoxicity by disulfiram involves Activating Transcription Factor 3. O’Brien A, Barber JEL, Reid S, Niknejad N, Dimitroulakos J. Anticancer Research. 32(7):2679-88, 2012.  
3. St. Germain C, Niknejad N, Ma L, Garbuio K, Hai T, Dimitroulakos J. Cisplatin induces cytotoxicity via the mitogen-activated protein kinase pathways and Activating Transcription Factor 3. Neoplasia 12(7): 527-38, 2010.     

Meet the Dimitroulakos Lab